OPRM1 (Opioid Receptor Mu 1)

Collectively, these findings suggest that chronic shoulder pain/disability in breast cancer survivors in this sample of South African patients is influenced by the combined effects of polymorphisms within the ABCB1-OPRM1-COMT genes. These observations present the potential for further translational research, personalized medicine, and pain management strategies to improve the long-term quality of life in breast cancer patients.

EA promotes remyelination in EAE mice by stimulating β-EP-mediated NSC proliferation and OPC differentiation. These findings reveal a novel neuroregenerative mechanism and support EA as a promising adjunctive strategy for demyelinating diseases such as MS.

Our study offers valuable insights into the molecular mechanisms of CIPN in breast cancer patients treated with taxanes. By identifying key molecular markers and pathways, such as CREB and opioid signaling, we provide initial evidence for hypothesis generation and future research. While these findings are correlative and require further validation, they highlight potential biological mechanisms and serve as a basis for validating candidates as biomarkers or therapeutic targets.

We applied a systematic, cross-modality platform to assess cell dynamics using spatial transcriptomics and uncover not only distinct spatially resolved transcriptome changes in opioid exposed mice, but also changes dependent on the Oprm1 variant. Collectively, our findings suggest that genetic risk for opioid dependence at the Oprm1 locus may be reflected more strongly in glial cell adaptations rather than neuronal dysfunction, emphasizing the importance of oligodendrocyte-mediated neuroimmune interactions in opioid dependence.

Emerging preclinical evidence suggests that opioids, particularly morphine, may facilitate breast cancer progression by enhancing cancer cell migration, angiogenesis, and immune evasion...In contrast, tramadol has shown potential immune-protective effects by preserving Natural Killer (NK) cell function and inhibiting adrenergic signaling; fentanyl and sufentanil exhibit variable impacts on tumor biology, necessitating further investigation...Future studies integrating single-cell transcriptomics and tumor microenvironment analyses will be critical in elucidating the molecular impact of opioids in breast cancer. Personalized pain management approaches tailored to genetic and clinical profiles may optimize oncological outcomes while preserving analgesic efficacy.

Genetic variations in OPRM1 and OPRD1 may play a role in pain perception and ADRs in colorectal cancer patients. These findings contribute to the understanding of pharmacogenomic factors in opioid therapy, emphasizing the need for further research to validate the clinical utility of these genetic markers.

This study contributes to understanding of the biological and functional roles of RNF128- and RPN1-dependent N-glycosylation. [BMB Reports 2024; 57(12): 546-552].

These findings suggest that morphine acts via a peripheral OPRM1-mediated mechanism to suppress CD8+ T cells, thereby fostering a pro-tumor-impaired immune response. Importantly, peripherally-restricted OPRM1 antagonism can effectively block this morphine-induced immunosuppression while still allowing for centrally-mediated analgesia, indicating a potential therapeutic strategy for mitigating the adverse effects of opioid pain relief in cancer treatment.

P=N/A, N=46, Completed, Boston Medical Center | Recruiting --> Completed | N=100 --> 46 | Trial completion date: Oct 2024 --> May 2024 | Trial primary completion date: Oct 2024 --> May 2024

Our study presents the results of an innovative model for predicting OUD in our setting. After external validation, it could represent a change in the paradigm of opioid treatment, helping clinicians to better identify and manage the risks and reduce the side effects and complications.

P=N/A, N=106, Not yet recruiting, Henan Provincial Chest Hospital; Henan Provincial Chest Hospital

Patients with cancer with the COMT alternate (A) allele have greater sickness response adverse effects, which may be responsible for the lower opioid doses observed. Significant results of two new COMT/OPRM1 genotype combinations are presented that have not previously been studied, with plausible phenotype descriptions suggested.